People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy -; proton beam therapy or intensity modulated radiation therapy (IMRT) -; achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Telix’s prostate cancer imaging kit set for FDA review – Pharmaceutical Technology
Telix already has an FDA-approved imaging agent, a gallium-68 gozetotide injection marketed under the brand name Illuccix. Image credit: Shutterstock / Ezume Images. A day
July 24, 2024